SCHEDULE 13G: MAK Capital Group Discloses 5.8% Passive Stake in Autolus Therapeutics plc
Beneficial Ownership Disclosure
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly disclosed a passive 5.8% beneficial ownership stake in Autolus Therapeutics plc, totaling 15,408,638 American Depositary Shares.
Summary
- MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership of Autolus Therapeutics plc.
- The Reporting Persons collectively own 15,408,638 American Depositary Shares (ADS), each representing one Ordinary Share, of Autolus Therapeutics plc.
- This aggregate amount represents 5.8% of the outstanding Ordinary Shares (including shares in the form of ADS) of Autolus Therapeutics plc.
- The calculation of the percentage is based on 266,141,411 ordinary shares outstanding as of May 7, 2025, as reported by Autolus Therapeutics plc in its Quarterly Report on Form 10-Q filed on May 8, 2025.
- The Reporting Persons hold shared voting power and shared dispositive power over all 15,408,638 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Autolus Therapeutics plc.
Sentiment
Score: 6
Explanation: The disclosure of a new significant passive institutional investor is generally a neutral to slightly positive event, indicating external validation of the company's value, though it does not imply active engagement or a change in company strategy.
Positives
- The disclosure of a significant passive stake by institutional investors like MAK Capital can be viewed as a vote of confidence in Autolus Therapeutics plc's long-term prospects.
- A new institutional investor on the shareholder register may attract further investor interest and potentially improve liquidity.
Industry Context
Autolus Therapeutics plc operates in the biotechnology sector, focusing on cell therapies. The entry of a new significant institutional investor like MAK Capital, even in a passive capacity, can signal growing confidence in the company's therapeutic pipeline or market position within the competitive biotech landscape.
Stakeholder Impact
- Shareholders: The entry of a new significant institutional investor may positively influence market perception and potentially share price, signaling increased institutional interest in Autolus Therapeutics plc.
Key Dates
| Date | Description |
|---|---|
| 05/07/2025 | Date as of which 266,141,411 ordinary shares were outstanding, used for percentage calculation. |
| 05/08/2025 | Date Autolus Therapeutics plc filed its Quarterly Report on Form 10-Q, reporting the outstanding share count. |
| 06/17/2025 | Date of event which required the filing of this Schedule 13G statement. |
| 06/25/2025 | Date the Schedule 13G statement was signed and filed by the Reporting Persons. |
Keywords
Autolus Therapeutics, MAK Capital, Schedule 13G, Beneficial Ownership, ADS, Ordinary Shares, Institutional Investor, Passive Investment, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.